Mannkind (MNKD) Construction in Progress (2021 - 2022)

Mannkind (MNKD) reported Construction in Progress of $7.7 million for Q1 2022, up 63.83% quarter-over-quarter from $4.7 million in Q4 2021.

Mannkind (MNKD) Construction in Progress (2021 - 2022) Analysis & Trends

Mannkind (MNKD) has 2 years of Construction in Progress data on file, last reported at $7.7 million in Q1 2022.

Construction in Progress for Q1 2022 came in at $7.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $7.7 million (changed N/A YoY), and the FY2021 annual result was $4.7 million, changed N/A from the prior year.
Construction in Progress rose to $7.7 million in Q1 2022 per MNKD's latest filing, from $4.7 million in the prior quarter.
Over five years, Construction in Progress peaked at $7.7 million in Q1 2022 and troughed at $1.6 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Mannkind	1.21 Bn	1.08 Bn	82.66 Mn	-

Download Data